We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+14.74%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$792M
AUM Growth
+$9.15M
Cap. Flow
+$37.1M
Cap. Flow %
4.68%
Top 10 Hldgs %
65.85%
Holding
54
New
9
Increased
12
Reduced
17
Closed
8

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$65.8M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.66M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.13M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$28.3M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.1M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$14.1M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 65.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
26
Veracyte
VCYT
$4.45B
$7.56M 0.95%
907,596
+597
+0.1% +$4.87K
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.04M 0.89%
+800,000
New +$5.13M
CASC
28
DELISTED
Cascadian Therapeutics, Inc.
CASC
$6.77M 0.85%
1,821,248
– –
VIVE
29
DELISTED
VIVEVE MED INC
VIVE
$5.71M 0.72%
796
-94
-11% -$701K
ARGX icon
30
argenx
ARGX
$55.2B
$4.57M 0.58%
+215,597
New +$4.49M
NVRO
31
DELISTED
NEVRO CORP.
NVRO
$3.72M 0.47%
+50,000
New +$4.01M
FBIO icon
32
Fortress Biotech
FBIO
$111M
$2.87M 0.36%
40,244
-26,200
-39% -$1.55M
CLLS
33
Cellectis
CLLS
$288M
$2.21M 0.28%
85,689
-11,407
-12% -$272K
PTCT icon
34
PTC Therapeutics
PTCT
$6.18B
$2.2M 0.28%
+120,000
New +$1.62M
SIOX
35
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.9M 0.24%
10,261
-37,812
-79% -$6.63M
SPY icon
36
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$1.46M 0.18%
+250,000
New +$59.9M
NDRM
37
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.33M 0.17%
44,516
-545,484
-92% -$14.1M
SRNE
38
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$832K 0.11%
416,230
-775,900
-65% -$1.51M
OTLK icon
39
Outlook Therapeutics
OTLK
$187M
$684K 0.09%
4,272
– –
ARRY
40
CALL
DELISTED
Array Biopharma Inc
ARRY
$587K 0.07%
500,000
-361,400
-42% -$2.96M
FOLD
41
CALL
DELISTED
Amicus Therapeutics
FOLD
$532K 0.07%
250,000
– –
TPST icon
42
Tempest Therapeutics
TPST
$14.3M
$489K 0.06%
+107
New +$453K
MDCO
43
CALL
DELISTED
Medicines Co
MDCO
$50K 0.01%
+200,000
New +$8.91M
ONSIW
44
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$40K 0.01%
233,333
– –
ONSIZ
45
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$22K ﹤0.01%
233,333
– –
AKBA icon
46
Akebia Therapeutics
AKBA
$338M
– –
-456,369
Closed -$4.2M
BPMC
47
DELISTED
Blueprint Medicines
BPMC
– –
-165,000
Closed -$6.6M
CRVS icon
48
Corvus Pharmaceuticals
CRVS
$1.1B
– –
-121,715
Closed -$2.53M
SGEN
49
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-450,000
Closed -$28.3M
BLCM
50
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-12,500
Closed -$1.54M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Avoro Capital Advisors held 54 positions worth $792M, up 1.2% from $783M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $37.1M of net new capital in Q2 2017, opening 9 new positions and adding to 12 existing holdings. Its largest new stake was Kite Pharma, Inc.: 806,750 shares worth $83.6M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 75% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $30.3M trimmed.

  • Avoro Capital Advisors's largest Q2 2017 buy was Kite Pharma, Inc.: 806,750 shares worth $83.6M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2017, an estimated $8.72M increase.
  • Avoro Capital Advisors's biggest Q2 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $30.3M.
  • Avoro Capital Advisors fully exited Seagen Inc. Common Stock in Q2 2017, selling an estimated $28.3M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $792M portfolio in Q2 2017.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q2 2017.
  • Avoro Capital Advisors's portfolio value rose 1.2% quarter-over-quarter to $792M.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.